TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens - PubMed (original) (raw)
doi: 10.1158/1535-7163.MCT-11-0762. Epub 2011 Dec 21.
Kohei Honda, Kouki Hikami, Hitoshi Miyashita, Isao Kaieda, Saomi Murai, Noriko Uchiyama, Maki Hasegawa, Tomohiro Kawamoto, Takashi Sato, Takashi Ichikawa, Sheldon Cao, Zhe Nie, Lilly Zhang, Johnny Yang, Keisuke Kuida, Erik Kupperman
Affiliations
- PMID: 22188812
- DOI: 10.1158/1535-7163.MCT-11-0762
TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens
Yuichi Hikichi et al. Mol Cancer Ther. 2012 Mar.
Abstract
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase involved in key processes during mitosis. Human PLK1 has been shown to be overexpressed in various human cancers, and elevated levels of PLK1 have been associated with poor prognosis, making it an attractive target for anticancer therapy. TAK-960 [4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-N-(1-methylpiperidin-4-yl) benzamide] is a novel, investigational, orally bioavailable, potent, and selective PLK1 inhibitor that has shown activity in several tumor cell lines, including those that express multidrug-resistant protein 1 (MDR1). Consistent with PLK1 inhibition, TAK-960 treatment caused accumulation of G(2)-M cells, aberrant polo mitosis morphology, and increased phosphorylation of histone H3 (pHH3) in vitro and in vivo. TAK-960 inhibited proliferation of multiple cancer cell lines, with mean EC(50) values ranging from 8.4 to 46.9 nmol/L, but not in nondividing normal cells (EC(50) >1,000 nmol/L). The mutation status of TP53 or KRAS and MDR1 expression did not correlate with the potency of TAK-960 in the cell lines tested. In animal models, oral administration of TAK-960 increased pHH3 in a dose-dependent manner and significantly inhibited the growth of HT-29 colorectal cancer xenografts. Treatment with once daily TAK-960 exhibited significant efficacy against multiple tumor xenografts, including an adriamycin/paclitaxel-resistant xenograft model and a disseminated leukemia model. TAK-960 has entered clinical evaluation in patients with advanced cancers.
Similar articles
- Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, Purkey A, Messersmith WA, Kuida K, Eckhardt SG, Pitts TM. Klauck PJ, et al. BMC Cancer. 2018 Feb 5;18(1):136. doi: 10.1186/s12885-018-4036-z. BMC Cancer. 2018. PMID: 29402316 Free PMC article. - Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1).
Nie Z, Feher V, Natala S, McBride C, Kiryanov A, Jones B, Lam B, Liu Y, Kaldor S, Stafford J, Hikami K, Uchiyama N, Kawamoto T, Hikichi Y, Matsumoto S, Amano N, Zhang L, Hosfield D, Skene R, Zou H, Cao X, Ichikawa T. Nie Z, et al. Bioorg Med Chem Lett. 2013 Jun 15;23(12):3662-6. doi: 10.1016/j.bmcl.2013.02.083. Epub 2013 Feb 27. Bioorg Med Chem Lett. 2013. PMID: 23664874 Clinical Trial. - NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J. Valsasina B, et al. Mol Cancer Ther. 2012 Apr;11(4):1006-16. doi: 10.1158/1535-7163.MCT-11-0765. Epub 2012 Feb 7. Mol Cancer Ther. 2012. PMID: 22319201 - Developments of polo-like kinase 1 (Plk1) inhibitors as anti-cancer agents.
Li S, Zhang Y, Xu W. Li S, et al. Mini Rev Med Chem. 2013 Dec;13(14):2014-25. doi: 10.2174/13895575113136660103. Mini Rev Med Chem. 2013. PMID: 24160708 Review. - Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.
Lee KS, Burke TR Jr, Park JE, Bang JK, Lee E. Lee KS, et al. Trends Pharmacol Sci. 2015 Dec;36(12):858-877. doi: 10.1016/j.tips.2015.08.013. Epub 2015 Oct 17. Trends Pharmacol Sci. 2015. PMID: 26478211 Free PMC article. Review.
Cited by
- The two sides of chromosomal instability: drivers and brakes in cancer.
Hosea R, Hillary S, Naqvi S, Wu S, Kasim V. Hosea R, et al. Signal Transduct Target Ther. 2024 Mar 29;9(1):75. doi: 10.1038/s41392-024-01767-7. Signal Transduct Target Ther. 2024. PMID: 38553459 Free PMC article. Review. - The role of primary cilia in thyroid diseases.
Tian Z, Li X, Yu X, Yan S, Sun J, Ma W, Zhu X, Tang Y. Tian Z, et al. Front Endocrinol (Lausanne). 2024 Jan 8;14:1306550. doi: 10.3389/fendo.2023.1306550. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38260150 Free PMC article. Review. - HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma.
Song Y, Lee SY, Kim S, Choi I, Kim N, Park J, Seo HR. Song Y, et al. Cancers (Basel). 2023 Jan 30;15(3):851. doi: 10.3390/cancers15030851. Cancers (Basel). 2023. PMID: 36765811 Free PMC article. - Present and Future Perspective on PLK1 Inhibition in Cancer Treatment.
Chiappa M, Petrella S, Damia G, Broggini M, Guffanti F, Ricci F. Chiappa M, et al. Front Oncol. 2022 Jun 2;12:903016. doi: 10.3389/fonc.2022.903016. eCollection 2022. Front Oncol. 2022. PMID: 35719948 Free PMC article. Review. - A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
Wang D, Veo B, Pierce A, Fosmire S, Madhavan K, Balakrishnan I, Donson A, Alimova I, Sullivan KD, Joshi M, Erlander M, Ridinger M, Foreman NK, Venkataraman S, Vibhakar R. Wang D, et al. Neuro Oncol. 2022 Mar 12;24(3):414-426. doi: 10.1093/neuonc/noab207. Neuro Oncol. 2022. PMID: 34477871 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous